Skip to content

Earnings call

Aurobindo Pharma Q3 FY26 earnings call: Aurobindo Pharma is on a trajectory to exceed 1 billion in annual European revenue by close of FY26, underpinned by execution across key European markets

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

The company is on a trajectory to exceed 1 billion in annual European revenue by close of FY26, underpinned by execution across key European markets. The company has manufacturing capacity exceeding 60 billion units, with further expansion underway, to support rising demand across markets while improving operating leverage. Consolidated revenue grew 8.4% year-on-year to 8,646 crores in the third quarter ended December 31, 2025, reflecting sustained business momentum through the nine months of FY26; growth was driven by European operations, stable U.S. based business and growth market operations. Core business demand in the third quarter ended December 31, 2025 was supported by volume expansion and recent product launches. The company continued to expand its presence in key markets such as Canada during the third quarter ended December 31, 2025.

The numbers management gave

Results

  • Consolidated revenue grew 8.4% year-on-year to 8,646 crores in the third quarter ended December 31, 2025, reflecting sustained business momentum through the nine months of FY26; growth was driven by European operations, stable U.S. based business and growth market operations.
    Show source
    • Our consolidated revenue for the quarter grew by 8.4% year-on-year to 8,646 crores, reflecting sustained business momentum through the nine months of FY26.
  • EBITDA was 1,773 crores with a margin of 20.5% in the third quarter ended December 31, 2025, growing 9% year-on-year.
    Show source
    • EBITDA for the quarter stood at 1,773 crores with a margin of 20.5%, demonstrating a 9% year-on-year growth.
  • Overall formulation business reported year-on-year growth of 10%, with revenue of Rs. 7,683 crores, contributing approximately 89% of total consolidated revenue in the third quarter ended December 31, 2025.
    Show source
    The overall formulation business reported a year-on-year growth of 10% with a revenue reaching Rs. 7,683 crores, contributing approximately 89% of the total consolidated revenue.
  • API business contributed 11% of overall revenue, amounting to Rs. 963 crores, in the third quarter ended December 31, 2025.
    Show source
    The API business contributed to 11% of the overall revenue, amounting to (Rs. 963 crores), in line with the ongoing market trends and prevailing pricing landscape.
  • U.S. revenue was USD 420 million, excluding gRevlimid, in the third quarter ended December 31, 2025.
    Show source
    U.S. formulation: U.S. revenue stood at USD 420 million, excluding gRevlimid, U.S. Oral Solid remained stable, demonstrating the strength and resilience over a diversified product portfolio.
  • U.S. injectable sales grew year-on-year by 17% in the third quarter ended December 31, 2025.
    Show source
    Our U.S. injectable sales also grew by year-on-year by 17%.
Show 16 more statements

Results

  • The company launched 9 new products and received 7 approvals in the third quarter ended December 31, 2025.
    Show source
    During the quarter, we launched 9 new products and received 7 approvals reflecting strong pipeline performance, coupled with sustained progress in regulatory approvals.
  • European business delivered 27% year-on-year revenue growth, amounting to Rs. 2,703 crores or 261 million in Euro terms in the third quarter ended December 31, 2025.
    Show source
    European Business: The European business maintained its strong momentum in growth, delivering 27% year-on-year revenue growth, amounting to Rs. 2,703 crores.
  • Growth markets revenue remained flat at Rs. 865 crores or USD 97 million in the third quarter ended December 31, 2025, driven by stable volume and a strong diversified commercial base across the strategic market.
    Show source
    Growth markets : Revenue from growth markets remained flat at Rs. 865 crores or USD 97 million, driven by stable volume and strong diversified commercial base across the strategic market.
  • ARV formulation revenue reached Rs. 376 crores or USD 42 million, with 22% year-on-year growth in the third quarter ended December 31, 2025; growth was driven by higher volumes and new tender wins across key markets over the medium to long term.
    Show source
    3 Aurobindo Pharma Limited 10 February 2026 ARV formulation: ARV formulation reached to Rs. 376 crores or USD 42 million with 22% year- on-year growth.
  • Gross margin was 59.7% in the third quarter ended December 31, 2025, supported by softer raw material prices and business mix.
    Show source
    Operational and financial highlight: Gross margin for that quarter stood at 59.7%, supported by softer raw material prices and business mix.
  • Gross contribution was Rs. 5,165 crores in the third quarter ended December 31, 2025.
    Show source
    Gross contribution stood at Rs. 5,165 crores.
  • Excluding g-Revlimid, Aurobindo Pharma's sales increased approximately by 9%, gross profit by 13% and EBITDA by 15% year-on-year in the third quarter ended December 31, 2025.
    Show source
    Excluding g-Revlimid, year-on-year basis, our sales have increased approximately by 9%, gross profit by 13% and EBITDA by 15% respectively.
  • R&D expenditure was Rs. 409 crores, amounting to 5% of total revenues, in the third quarter ended December 31, 2025.
    Show source
    R&D expenditure was Rs. 409 crores, amounting to 5% of the total revenues, thereby reinforcing our commitment on continue to build a robust pipeline of high -value products, including complex generics and specialty therapie s. Net capex for the quarter stood at USD 79 million, in line with our strategic priorities of enhancing our manufacturing capabilities, strengthening compliance and accelerating automation.
  • Average finance costs were 4.9% in the third quarter ended December 31, 2025.
    Show source
    On average, finance costs were 4.9%.
  • Net profit for the nine months period ended December 31, 2025 was Rs. 910 crores, after a one-time cost of Rs. 65 crores due to change in the labour code amendment.
    Show source
    Net profit for the period stood at Rs. 910 crores, after one-time cost due to change in the labour code amendment, Rs. 65 crores.
  • The company says Lyfius has a tax rate around 15% and Qule also 15%, and the company will move towards a tax rate around 25% over a period of time.
    Show source
    Otherwise, the tax rate for the entire company, in fact Lyfius the tax rate is around 15% and Qule also 15%., so we will move towards that.
  • The company launched about nine products in the US in the quarter ended December 31, 2025, and believes a similar launch trend will continue for the next 12 months.
    Show source
    So we launched about nine products in the last quarter ending December.
  • Pen-G facility was fully utilized in the last quarter.
    Show source
    S. Subramanian: I think the last quarter we are fully utilized.

Money and capital

  • Net capex was USD 79 million in the third quarter ended December 31, 2025, in line with its strategic priorities of enhancing manufacturing capabilities, strengthening compliance and accelerating automation.
    Show source
    R&D expenditure was Rs. 409 crores, amounting to 5% of the total revenues, thereby reinforcing our commitment on continue to build a robust pipeline of high -value products, including complex generics and specialty therapie s. Net capex for the quarter stood at USD 79 million, in line with our strategic priorities of enhancing our manufacturing capabilities, strengthening compliance and accelerating automation.
  • The company generated net cash inflow of USD 118 million during the third quarter ended December 31, 2025; its net cash position was USD 170 million as of September 30, compared to USD 251 million as of 31st March 2025, including investment and appropriating for the purchase consideration of domestic pharma acquisition.
    Show source
    We generated net cash inflow of USD 118 million during the quarter, resulting in improved net cash position, including investment and appropriating for the purchase consideration of domestic pharma acquisition of USD 251 million as of 31st March 2025, compared to USD 170 million as of September 30, 2025.
  • The company may incur between USD 80 million and USD 120 million in CapEx over the next two years.
    Show source
    S. Subramanian: Yeah, Jigar, the CapEx, as Satakarni says USD 100 to 120 million type, probably we may be incurring anywhere between 80 to 120 million in the current… the next two years.

What it expects ahead

What management expects

  • The company is on a trajectory to exceed 1 billion in annual European revenue by close of FY26, underpinned by execution across key European markets.
    Show source
    Consistent execution across key European markets firmly underpins our trajectory to exceed 1 billion in annual European revenue by close of FY26.
  • The company expects to produce more than 10,000 metric tonnes on an annualised basis over the next 12 months based on its current production level at the Pen-G facility.
    Show source
    Based on our current production level, we expect to produce more than 10,000 metric tonnes on annualised basis over the next 12 months.
  • The company expects to ramp up PEN-G, 6APA and Amoxicillin to nearly 65 to 70% by March ‘26, against the last year average of 42%.
    Show source
    We expect to ramp it up to nearly 65 to 70% by March ‘26 against the last year average of 42%.
  • The company hopes the 6APA pricing issue will be resolved by end of March or maybe by April following correction in the MIP.
    Show source
    And with the correction in the MIP, etc, hopefully this should get resolved by end of March or maybe by April.
  • The company expects to convert its biosimilar efforts into commercial momentum by 2029, its biotech inflection year, with four biosimilars brought to market (read as approval) in the last one year and two or three more ready for filing in Europe and the US.
    Show source
    All the efforts that we have made in bringing four biosimilars into the market (read as approval) in the last one year, and with two or three more ready for filing in both Europe and US, we expect to ramp all this up, convert this into some sort of commercial momentum by 2029, which is our inflection year, I believe.
  • The company is confident of achieving its internal target margin of 20%-21% range in FY26.
    Show source
    5 Aurobindo Pharma Limited 10 February 2026 Taken together, these initiatives provide strong earnings growth visibility and reinforce our confidence in achieving our internal EBITDA margin target of mostly on the higher side of 20% to 21% for FY26.
Show 2 more statements

What management expects

  • The company remains confident of achieving EBITDA break-even in Q4 and meaningfully contributing to bottom-line EBITDA in the next year.
    Show source
    We remain confident of achieving EBITDA break-even in Q4 and meaningfully contribute to the bottom-line EBITDA in the next year.
  • The company plans to complete validation campaigns for Omalizumab and Denosumab biosimilars and start filing them in Europe and the US from June/July; the resulting capacity freeing and commercialization readiness are expected over the medium term.
    Show source
    So, over the medium term, with the Omalizumab and Denosumab biosimilars that I was providing guidance for, which I have to complete the validation campaigns and then start filing them from June/July in both Europe and US, the capacities will get freed up, and the commercialization readiness will become more real.

What it is building and selling

Projects and capacity

  • The company has manufacturing capacity exceeding 60 billion units, with further expansion underway, to support rising demand across markets while improving operating leverage.
    Show source
    With manufacturing capacity exceeding 60 billion units and further expansion underway, we are well-positioned to support rising demand across various markets while improving operating leverage.
  • Based on January production, Aurobindo Pharma's Pen-G production is nearly 9,000 to 10,000 (MT) on an annualized basis.
    Show source
    We are fully utilized and we, see we are now, based on the January production, we are nearly, nearly 9,000 to 10,000 (MT) annualized number.
  • OSD facility in China is ramping up toward capacity of 2 billion, backed by European approval of 10 products and 3 local product approvals.
    Show source
    Our OSD China facility continues to progress steadily, advancing towards an annual capacity of 2 billion units, currently supported by EU approval for 10 products and 3 local product approval.
  • Dayton facility has transitioned into a commercial phase with manufacturing underway and will begin contributing revenues significantly from FY27 onwards.
    Show source
    The Dayton facility has successfully transitioned into a commercial phase with manufacturing underway and will begin contributing revenues significantly from FY27 onwards.
  • Raleigh facility remains on track pending regulatory clearance, and the company is prepared to scale up operations.
    Show source
    In parallel, Raleigh facility remains on track pending regulatory clearance and we are fully prepared to scale up the operations.
  • The company has already achieved break-even on the Pen-G facility and has started making a little bit contribution now itself.
    Show source
    To give you some more color, we have already (achieved break-even) on the Pen-G facility and we started making a little bit contribution now itself.
Show 4 more statements

Projects and capacity

  • The company ramped up Pen-G production significantly in January and hopes to ramp it up further in the coming months depending upon availability of stock in the market.
    Show source
    We have already ramped up significantly in the month of January and hopefully this will get further ramped up in the coming months, depending upon the availability of the stock in the market.

Demand and pricing

  • Core business demand in the third quarter ended December 31, 2025 was supported by volume expansion and recent product launches.
    Show source
    During the quarter, our core business continued to see healthy demand supported by volume expansion and recent product launches.

Segments

  • The company continued to expand its presence in key markets such as Canada during the third quarter ended December 31, 2025.
    Show source
    We have continued to expand our presence in key markets such as Canada during the quarter.
  • About 60% of Aurobindo Pharma's Europe sourcing comes from in-house sources, and the balance comes from third-party sites; the company is steadily transferring key third-party products to its sites.
    Show source
    Closer to 60% of the sourcing happens from in-house sources, and steadily we are also transferring the third- party products, the key ones, to our sites.

Risks, rules and outside factors

Outside factors

  • The company says 6APA prices have been going well below the cost of manufacture internationally due to predatory pricing.
    Show source
    9 Aurobindo Pharma Limited 10 February 2026 However, where we have been losing out is on the 6APA prices where there is a predatory pricing and it is going well below the cost of manufacture internationally also.

Rules and policy

  • The Government of India issued a notification introducing a one-year CIF on minimum import price for Pen-G, 6 APA and Amoxicillin.
    Show source
    The Government of India issued a notification introducing a one-year CIF on minimum import price for Pen-G, 6 APA and Amoxicillin.
  • The company expects the Government of India's decision to boost domestic manufacturing of APIs and KSMs and reduce supply disruption risks while creating India's self-reliance in antibiotics.
    Show source
    Finally, we consider this decision by Government of India strategically important for creating India's self-reliance in antibiotics and reducing supply disruption risks and will boost the domestic manufacturing of APIs and KSMs.

Everything else said on the call

Group structure

  • The company expects the Lannett transaction process to be completed early in the next fiscal year, that is Q1 of ‘27.
    Show source
    We feel confident that this process will be completed early in the next fiscal year, that is Q1 of ‘27.
  • Lannett acquisition further strengthened the U.S. business, subject to regulatory approvals. Aurobindo Pharma USA, Inc. (“Aurobindo USA”), a wholly owned subsidiary of Aurobindo Pharma Limited, received U.S. Federal Trade Commission (FTC) approval to proceed with the acquisition of Lannett Company LLC (“Lannett”).
    Show source
    The Lannett acquisition further strengthened the US business, and this is subject to regulatory approvals.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Tushar Manudhane: Thanks. Thanks for the opportunity. Sir, with respect to Eugia III inspection, if you could share some color in terms of the nature of observations. Secondly, if implementing any measures to address th is issues, will this require certain, let us say, temporary stoppage of production or anything of that sort, if you could throw some light on that?

    Answer, yugandhar puvvala

    Yugandhar Puvvala: Yeah, I think, Tushar, we have already clearly mentioned this, stating that these are all procedural observations. There is no stoppage of production, no stoppage of any nature and these are procedural and technical. And we are very confident of responding within 15 working days to USFDA. I do not see any issue.

  2. Question

    Tushar Manudhane: So, that way the production also will be on the continued process per se?

    Answer, yugandhar puvvala

    Yugandhar Puvvala: That is right. I think we are very, very clear. I think last time inspection was completely different and this time inspection is, it is very positive from that perspective that we do not have any data integrity issues, which was the issue last time unfort unately. And these are all procedural in nature and procedural means like it requires a one week or 10 days, some SOP changes, some corrections here and there. So, absolutely no problem. Tushar Manud hane: That is good to hear, sir. And just one clarification from the opening remarks.

  3. Question

    Damayanti Kerai: Good morning and thank you for the opportunity. This is Damayanti from HSBC Securities. My first question is again on Eugia. So, as you mentioned, the observation seems to be procedural in nature and it might be resolved within your stipulated timeline. But given we are yet to get full clearance from the FDA, what kind of trajectory we should build for or we should assume for the US injectable sales? In your opening remarks, obviously, you mentioned this segment has seen good pickup. So, if you can just talk a bit about it.

    Answer, yugandhar puvvala

    Yugandhar Puvvala: Yeah, Damayanti, like see, these are procedural in nature and we will respond and we are cautiously optimistic about the future of this facility. But ultimately, US FDA has to take a decision in terms of the warning letters. So, I cannot comment on what exactly they will do, but we feel confident that we will be in a position to respond. And in my view, probably like next year will be again same double-digit growth, what with the ramp up of supplies and other stuff happening from various other facilities. So, it should be in that same trajectory till the time the warning letter gets lifted. If in case if the warning letter gets lifted, then it will be a different this thing, that we can talk in subsequent quarters. But at this juncture, we are cautiously optimistic.

  4. Question

    Damayanti Kerai: 17%. Okay. So, that's good to hear. My second question is on your Europe business. So, although in reported numbers, I think reported terms, growth looks very strong. In constant currency, we are seeing this segment growing in low double digit for last two quarters or so. So, with now the China supply improving, how do you see this busin ess ramping up and say from current low double digit in constant currency, what kind of growth we can assume once we see higher supplies coming from China?

    Answer, v muralidharan

    V. Muralidharan: Good morning. Murali here. Low double digit in itself is well ahead of the market growth rate. So, this is what we are tracking. And all of our leading geographies, whether it is France, Portugal, Germany, and Netherlands, they are all showing double digit growth. And of course, with more launches happening and 7 Aurobindo Pharma Limited 10 February 2026 supplies from China, we expect to grow further. And several launches are lined up, both yet to launch and some of the loss of exclusivity products.

    Answer, v muralidharan

    So, we expect further ramping up in the coming period.

  5. Question

    Damayanti Kerai: So, trajectory should improve as China supply picks up. That's what we should look forward for.

    Answer, v muralidharan

    V. Muralidharan: Definitely. This is what the trend we have been demonstrating if you really observed from the last couple of years, Q-on-Q, and we will continue to maintain that momentum.

  6. Question

    Damayanti Kerai: Injectable one, yes.

    Answer, yugandhar puvvala

    Yugandhar Puvvala: Yeah. Injectable one, like we have already filed 3 products and some 10 more products are under filing. We expect a slow commercialization to happen in next year, FY27. And because we are going to file a very, very important product from this facility, because we have a cartridge line where like we will be taking all the GLP -1 products from there and we'll be filing. And we have a PFS, we have a BFS and total , so, it will be 8 lines by end of this year, this calendar year. And that is what we want to restrict it to, so that the ramp up should happen starting from FY27 and we should take full benefits starting FY28.

  7. Question

    Neha Manpuria: Thanks for taking my question. My first question is on Lannett. Could you give us an update on where we are in the approval process from the FTC and when should we expect the completion of that transaction? And just to follow up on Lannett, you know, in your view, what would be the rough overlap between the L annett portfolio and Aurobindo portfolio that, you know, FTC could probably look at?

    Answer, swami iyer

    Swami Iyer: Thanks, Neha, for the question. Right now, we are actively engaging with the FTC through our attorneys and we are very pleased with the progression of the process to this 8 Aurobindo Pharma Limited 10 February 2026 point. We feel confident that this process will be completed early in the next fiscal year, that is Q1 of ‘27. As far as the overlap is concerned, you know, there are no surprises, there are no negative surprises. That is all I can say because obviously, this is a very confidential matter. I cannot disclose it. But we are quite pleased with the way it has progressed and with, like I said, there are no negative surprises.

  8. Question

    Neha Manpuria: Understood. So, I should assume that, you know, there is no risk from an FTC perspective in terms of timelines for the closure of this deal?

    Answer, swami iyer

    Swami Iyer: At this point, we are not looking at it. In fact, we are looking for a closing sometime soon. When I say soon, it is, like I said, in the first quarter of ‘27.

  9. Question

    Neha Manpuria: Understood. Understood. That is very helpful, sir. My second question is on the Pen-G capacity. Subbu sir, you know, roughly what would have been the EBITDA impact from the P en-G facility in fiscal ‘26? And as we think about the 10,000 tons production that you have mentioned over the next year, at what point do you see this actually start reflecting in the gross margins and, you know, possibly even external sales? You know, how should I think about how we monetize this capacity?

    Answer, s subramanian

    S. Subramanian: You see, as I said, you know, while we have been improving the yields consistently and increasing the production this quarter, obviously, the MIP is having a, I mean, compared to the current prices, the MIP prices are a little bit more. So, the full impact of it, we will be seeing it from the first quarter because there is already a stock available in the market, which hopefully will get consumed by end of February or mid of March. So, you should start seeing the improvements in April onw ards.

  10. Question

    Neha Manpuria: And what would be the EBITDA impact in your assessment from, you know, the Pen-G capacity, you know, this year? I mean, what would be a rough assessment of how much burn we have seen from that facility?

    Answer, s subramanian

    S. Subramanian: I think we should be getting a good EBITDA and you are already knowing the numbers while we may not like to specifically talk about the EBITDA numbers, but it is well- known based on the current market price and the MIP price, etc. Even assuming some discount, we could see a better improved EBITDA in the coming year.

Show 22 more questions
  1. Question

    Neha Manpuria: And is it fair to assume that when you say we'll start seeing an impact of this from first quarter, you know, the facility will break even in first quarter FY27?

    Answer, s subramanian

    S. Subramanian: Let me put it like that. To give you some more color, we have already (achieved break-even) on the Pen-G facility and we started making a little bit contribution now itself. 9 Aurobindo Pharma Limited 10 February 2026 However, where we have been losing out is on the 6APA prices where there is a predatory pricing and it is going well below the cost of manufacture internationally also. And with the correction in the MIP, etc, hopefully this should get resolved by end of March or maybe by April. You got it?

  2. Question

    Neha Manpuria: Understood, understood. So, I should start assuming 6APA sales, external sales from first quarter as well then in that case.

    Answer, s subramanian

    S. Subramanian: Correct. Because there is enough stock in the market and at low prices.

  3. Question

    Bino Pathiparampil: Hi, good morning. Sub bu sir, just to follow up, this Pen-G sale for the quarter, how much was produced and was it also, was it sold or fully utilized internally?

    Answer, s subramanian

    S. Subramanian: I think the last quarter we are fully utilized. We are fully utilized and we, see we are now, based on the January production, we are nearly, nearly 9,000 to 10,000 (MT) annualized number. We have gone to that extent. We have already ramped up significantly in the month of January and hopefully this will get further ramped up in the coming months, depending upon the availability of the stock in the market. So, we will ramp up in such a manner there is no over material available like that.

  4. Question

    Bino Pathiparampil: Understood.

    Answer, s subramanian

    S. Subramanian: But one good thing is the yields are improving, the production has stabilized fully. And it is a question of we need to put more fermenters and then produce the maximum capacities. Two things, one is utilization of all the fermenters, and the second factor is the yield improvement. Yield improvement we have been achieving, progressing well and full deployment of the fermenters, we are, we are in the process only. We will do it and ramp it up the way, the time we need to ramp it up.

  5. Question

    Bino Pathiparampil: Got it. S ir, what I was wondering is, you know, last quarter the MI P was not in place, so the market price was low. So , using our in-house Pen-G, did it really help the margins? Because from outside you would have probably… S. Subramanian: No, as I told you, Pen-G, we have been making, I mean, we are making a breakeven of slight profit.

    Answer, s subramanian

    It's a question of 6APA across the market and the resulting Amoxicillin price, which has really put the entire market at a loss. So that is getting corrected. Hopefully by April it should get corrected fully. 10 Aurobindo Pharma Limited 10 February 2026 Bino Pathiparampil: No, you break even, I understand that, but since the market prices were lower for the entire product basket, not just Pen-G or 6APA.

  6. Question

    Bino Pathiparampil: No, no, overall gross profit.

    Answer, s subramanian

    S. Subramanian: Overall, I think with the improved performance of the Pen-G and the related products, I think our losses, whatever the losses we have incurred has come down and which will turn into positive and this will help . And overall, Yugandhar also said , the injectable business is expected to go up and every business is working , and Murali has said that he is working on a double-digit growth, etc. So , all put together, I think we should be able to show a sustainable improvement in the EBITDA margin and the overall pr ofitability.

  7. Question

    Bino Pathiparampil: Got it. And one last small question, there is this product Pomalidomide - Pomalyst, which is opening up for gener ic competition soon anytime now, are we part of that first to market launches?

    Answer, yugandhar puvvala

    Yugandhar Puvvala: Yes, we'll be launching and we have already prepared for the launch.

  8. Question

    We've been seeing a reasonably elevated tax rate for last four quarters. And second, just following up on the earlier participant, not specifically for Pen-G, but really, you know, various capacities are in the process of ramp up – Lyfius, Qule, Auroactive, China, Dayton, Raleigh, (Eugia) Steriles. So just wanted to get a sense on what's the EBITDA burn of all these businesses which are in the ramp up phase, probably for nine months of FY26 or your estimate for FY26?

    Answer, yugandhar puvvala

    Yugandhar Puvvala: Subbu, this question is for you. I think he's asking EBITDA burn because of various initiatives.

    Answer, s subramanian

    S. Subramanian: Yeah. So, Tarang, the first question is on the tax rate. What has happened is today, CuraTeQ, today Lyfius, all these are independent companies, right. We have incurred losses on account of the ramping up and other things, and CuraTeQ on account of the R&D cost and other things, right. So ideally for the losses, we should have taken a tax credit, but we have been very conservative in our accounting. So, we are not taking the tax credit. Once we start making profit we'll take that tax credit with a retrospective effect.

    Answer, s subramanian

    So, that is the reason why you are seeing a higher tax rate. Otherwise, the tax rate for the entire company, in fact Lyfius the tax rate is around 15% and Qule also 15%., so we will move towards that. Over a period of time, we will be around 25%. But today we are in a ramping -up phase, and that is the reason you are seeing it. So nothing to worry about it. Okay?

  9. Question

    On the biosimilars business, we saw an announcement around vaccine restructuring. And second, I was curious for Lucentis, is the Phase 3 through EMA waived? Dr. Satakarni Makkapati: Hi, this is Satakarni.

    Answer, satakarni makkapati

    I would answer your first question. With the AuroVaccines merger, the intent is consolidating and improving our utilization of the existing capabilities that were built in Auro Vaccines. Essentially, the idea is to retain some flexibility to repurpose the capacities that we have built there from 2018 to the COVID period, as these capacities, some of them, can also be needed to support the future biosimilars roadmap. So, in the nu tshell, from the board and management, this is more 12 Aurobindo Pharma Limited 10 February 2026 about us looking into operational efficiency and agility, but not a change in strategic direction. So I hope this answers the part 1 of your question. What was part 2?

  10. Question

    Tarang Agrawal: For ranibizumab, is the Phase 3 waived in Europe? Dr. Satakarni Makkapati: No. So Ranibizumab is a product that goes into the eye.

    Answer, satakarni makkapati

    So it’s an ocular product used for wet AMD. So essentially, you need to inject the drug into the (vitreous cavity near the) retinal nerve of the eye. That requires a small minor surgical procedure, which is done in a clinical setting. So the Phase 3 is not waived for such products because you can’t do a PKPD study of such ocular products that gets injected into (the vitreous cavity near) the retinal nerve of the eye in healthy volunteers. So you will not have any volunteers to do this study. And hence, a Phase 3 for products like Ranibizumab will not have a waiver. Does that answer your question?

  11. Question

    Tarang Agrawal: Got it. Yes, yes, understood. Thank you. Last question on the US generics business. You know, up till calendar year ‘24, OTC was doing about $100 million of revenue. Just curious, how has that played out for calendar year ‘25, and what’s outlook for calendar year ‘26? Thank you.

    Answer, swami iyer

    Swami Iyer: Thanks, Tarang. We don’t normally talk about the dollar value for separate set of business. But I can tell you for the last couple of quarters or three quarters, OTC has really picked up, and we are looking at it as a fast-growing segment within the US, and we expect very good momentum in the sales and volumes for the OTC business.

  12. Question

    Shyam Srinivasan: Yeah, hi, good morning. Thank you for taking my question. Satakarni sir, just again on the biosimilar journey, now in the next 12 months, what are some of the milestones and timing that we need to keep in mind? And any way to kind of assess how large this could be for us over time, maybe fiscal ‘27 and over time? Dr. Satakarni Makkapati: Good morning, Shyam.

    Answer, satakarni makkapati

    In terms of milestones, Shyam, in the last quarter we have announced (the) first Canadian approval (for Dyrupeg), which is an important milestone for us, on the back of the four biosimilar approvals that we had in the European Economic Area. So we are preparing some momentum in Europe and growth markets through these approvals, which will be translating and converting into launches in this year. We have already built our first product. The previous quarter, we have… we are trying to execute multiple things. Bevqolva, which is Bevacizumab biosimilar, is already launched in the UK. Dazublys, which is our Trastuzumab biosimilar, was launched in the Baltics territory through a partner. This means we are moving from the readiness or the development phase, to real on-the-ground commercialization.

    Answer, satakarni makkapati

    Beyond this, (we also…) our strategy in the European Economic Area extends far beyond simply selling biosimilars through our subsidiary. So, we aim to achieve comprehensive coverage across the European Economic Area, across LATAM markets, and also in Canada. In fact, in LATAM, we are making a stepwise and disciplined approach country by country. We 13 Aurobindo Pharma Limited 10 February 2026 just won a tender in Mexico, which we have to service in this year. So, we have made a strong start with Mexico. We are also making a foray into Brazil. In fact, we have a GMP ANVISA inspection announced in May, which will then lead the path towards (potential) approval of at least four products.

    Answer, satakarni makkapati

    So, over the medium term, with the Omalizumab and Denosumab biosimilars that I was providing guidance for, which I have to complete the validation campaigns and then start filing them from June/July in both Europe and US, the capacities will get freed up, and the commercialization readiness will become more real. I believe 29 (2029)… to answer the second part of your question, as I have always stated, 29 (2029) would be the inflection year for biotech. All the efforts that we have made in bringing four biosimilars into the market (read as approval) in the last one year, and with two or three more ready for filing in both Europe and US, we expect to ramp all this up, convert this into some sort of commercial momentum by 2029, which is our inflection year, I believe. Does that answer your question?

  13. Question

    Shyam Srinivasan: Yeah, thank you, Dr. Satakarni. Just one sub-question before I go to the second one. This budget announcement of this BioShakti, Dr. Satakarni, anything… ? I know it’s early and maybe the details are not yet out for biomanufacturing in the country. You know, anything that you have, any insights from industry discussions? Or if you were to say or recommend to the government, what would be some of those things? Dr. Satakarni Makkapati: Very interesting question.

    Answer, satakarni makkapati

    I get asked this question in the last 2-3 days. Broadly, Shyam, I speak for myself and not for Aurobindo here. Broadly, initiatives like Biopharma Shakti are directionally positive for the sector, if executed well, and that’s my big takeaway… if executed well, it has the potential to strengthen the ecosystem, biotech ecosystem, in terms of… from the fine script what I read, in terms of skill development, the clinical trial sites, and how we go about conducting clinical trials, and the availability of the sites, faster translation from development to manufacturing, and let me remember… the predictable regulatory and quality environment that the government wants to create around this initiative. So for the biosimilars and biopharma i ndustry, I think the biggest takeaway will be an improved ecosystem, maybe into the beginning of the next decade, if it is implemented well. The challenge is, therefore, can we develop a stronger local capability in clinical development? When I say clinical development, do the trials that we do for complex biologics and biosimilars and new chemical entities in India stand the scrutiny and rigor of the agencies like FDA and EMA? Are many companies going to achieve that sort of skill (expertise/competence)?

    Answer, satakarni makkapati

    That’s question one. Then I believe this also helps build stronger local capability in single -use and critical consumable supply chains. As you know, during COVID, the industry in general has suffered from dependency on the West on single -use bags, filters, and resins, which a re so vital to delivering a drug and purifying them or producing them. And hopefully, the commentary in the Biopharma Shakti about skill development, because there’s a lack of human resources pool right now that can really help us compete with the evolved (biotech) industry in the West. So, I believe these are the three big takeaways: an improved ecosystem in terms of local capability building process and clinical development, innovation, single -use (and) critical consumable supply chains, etc. 14 Aurobindo Pharma Limited 10 February 2026 So what is important, again, to summarize, is the regulated markets will continue to require extremely stringent quality systems and rigor in GMP and GCP compliance. So, the success of Biopharma Shakti will depend on the execution. So let’s wait and watch.

    Answer, satakarni makkapati

    It’s just been, I think, two weeks, so let’s wait and watch. I am supportive of the tailwind it brings, especially when people like you ask the questions, which means you are looking forward to the tailwinds that it will bring. So let’s wait and watch that it translates into real results.

  14. Question

    Shyam Srinivasan: Thank you. Helpful. So just my last question to Subbu sir on the balance sheet, our net cash. I know there’s a Lannett acquisition still. But just want to understand from an outlook perspective on M&A, or what are some of the key priorities for us apart from CapEx and dividends, what are some of the key priorities for us as we look forward?

    Answer, s subramanian

    S. Subramanian: So Shyam, which I told you earlier also, we are not going for any major greenfield project other than whatever we are committing to TheraNym which is the biologics which Satakarni has informed. Otherwise, we are not going for any major organic. In terms of the inorganic, yeah, we keep on looking at it, but it is not that we need to do it urgently, etc. If we get the targets at the right price and to our strategy, fitting into our strategy, we will look into that. I think this is the main thing actually in ter ms of the capital allocation.

  15. Question

    Kunal Dhamesha: Yeah. Sir, just one question on the Pen -G and 6-APA. Since the prices of those imports had started coming down at the start of FY26 or the end of FY25, and we have imported little bit of 6 -APA in FY26, so is it fair to say that some of the gross margin improvement that we are baking in from the internal consumption from our facility is already there in the numbers? Because we are already getting a lower price imports, right?

    Answer, s subramanian

    S. Subramanian: Kunal, your question is right. That was the scenario one month to one and a half months back, but now the prices have started going up, okay? And whatever may be the production, We are anyway not going to buy it from them unless it is required, absolutely essential for various reasons, right? We will be producing, and our cost of production is also coming in line. So we should be seeing an improvement in the gross margins very clea rly going forward, right? That is the thing.

  16. Question

    Kunal Dhamesha: Okay, and so the MIP, when you would have made the representation to the government, what would be the basis of that? Would that be like the cost of production plus a decent profitability? Is it on that basis that the government would have decided based on your representation, or there are more factors into consideration?

    Answer, s subramanian

    S. Subramanian: Kunal, your question is absolutely right. But since I’m privy to certain information which has been worked along with the government, I am unable to disclose anything further on this.

  17. Question

    Jigar Valia: Yes, thank you so much for the opportunity. One question is with regards to the Lannett acquisition. The settlement amount of the fines. Is it final, or it can increase? And will it get adjusted in the price or not?

    Answer, swami iyer

    Swami Iyer: The settlement of Lannett is their liability, and Aurobindo is in no way liable, nor does it change the math.

  18. Question

    Jigar Valia: Okay, so the price also remains the same, while these will be settled independently.

    Answer, swami iyer

    Swami Iyer: Yeah, till today, I mean, till the actual acquisition happens, and any liability till that date will be that of Lannett. Jigar Valia: Okay, with regards to the PLI amount, when and how much are we expecting to come from the government?

    Answer, s subramanian

    S. Subramanian: So it is like this, Jigar. As per the government, it is Rs. 240 crores for every 10,000 MT, right, And as and when we produce the quantity, it will proportionately come.

  19. Question

    Jigar Valia: Got it, and we are already at nine, ten thousand you’ve mentioned kind of, so.

    Answer, s subramanian

    S. Subramanian: Absolutely. You can see… I mean, hopefully everything goes well, we should be able to see the full year… next year, we should be able to see the full amount.

  20. Question

    Nitin Agarwal: Right, right. And the last one on this, on for Europe, what kind of sourcing do we do? What proportion of our supplies are done from India, and how much do we source in Europe itself?

    Answer, v muralidharan

    Closer to 60% of the sourcing happens from in-house sources, and steadily we are also transferring the third- party products, the key ones, to our sites. And the balance comes from third-party sites.

  21. Question

    Nitin Agarwal: So how many new launches are we expecting in the US market in FY27, sorry?

    Answer, swami iyer

    Swami Iyer: So approval is one thing, and then we have the launches, because some of the launches could be what is approved, we may be launching later. So we launched about nine products in the last quarter ending December. We believe similar kind of trend would continue for the next 12 months. On a yearly basis, if you multiply, that’s what we can look at.

  22. Question

    Jigar Valia: Yes, sir, thank you for the follow-up. It is a follow-up on the previous question only. With regards to this USD 120–130 million, how much would have come in by now, and how much would come in FY27? And if I had to assume that these are for two products, and if there is a product addition, then another Rs. 300-400 crores of additional would one should budget with every new product?

    Answer, s subramanian

    S. Subramanian: Yeah, Jigar, the CapEx, as Satakarni says USD 100 to 120 million type, probably we may be incurring anywhere between 80 to 120 million in the current… the next two years.

Questions about this call

When was the Aurobindo Pharma Q3 FY26 earnings call transcript filed?
Aurobindo Pharma filed the transcript with the exchange on 16 Feb 2026. This page is built from that transcript.
What does this page list?
45 statements from the transcript across 9 topics, 36 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 32 questions and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Aurobindo Pharma Q3 FY26 concall: Aurobindo Pharma is on a trajectory to exceed 1 billion in annual European revenue by close of FY26, underpinned by execution across key European markets · DalalOS